Accelevir Diagnostics
Edit info- Founded: 2015
- Location: Baltimore, MD
- Employee range: 1-50
- Funding: <10M
accelevirdx.com linkedin.com job board
About:
Accelevir Diagnostics is developing methods to detect rare analytes in infectious diseases. To reduce the spread of infectious diseases, assays are required that enable quick and accurate diagnostics. Combining expertise in virology, immunology and assay commercialization, Accelevir is creating scalable assays that can identify difficult to detect pathogens. The technology employed includes droplet-digital PCR, qPCR and sequencing that offer high sensitivity. Accelevir is initially focusing on advancing new assays for persistent HIV-1, the virus that causes AIDS, and other clinically important viral infections. These assays can be used to support basic science research and to evaluate clinical trials.
Jobs:
News:
HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation - nejm.org
googlenews
Feb 14, 2024
Science/business updates
external-link
Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs
web
Jan 2, 2025
Science/business updates
external-link
Noble Life Sciences Inc on LinkedIn: Noble Life Sciences at ASGCT
crunchbase
May 7, 2024
Science/business updates
external-link
Wedded: Michelle Kim and Gregory Laird were a natural match - Baltimore Sun
googlenews
Jun 24, 2016
None of the above
external-link
31 startups that Baltimore research institutions should be very proud of - Technical.ly
googlenews
Sep 28, 2016
Science/business updates
external-link
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
web
Jan 2, 2025
Science/business updates
external-link
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
web
Jan 2, 2025
Science/business updates
external-link
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
web
Jan 2, 2025
Science/business updates
external-link
Distinct viral reservoirs in individuals with spontaneous control of HIV-1
web
Jan 2, 2025
Science/business updates
external-link
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo - eClinicalMedicine - The Lancet
googlenews
Nov 29, 2021
Science/business updates
external-link
A quantitative approach for measuring the reservoir of latent HIV-1 proviruses
web
Jan 2, 2025
Science/business updates
external-link
Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells
web
Jan 2, 2025
Science/business updates
external-link
Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
web
Jan 2, 2025
Science/business updates
external-link
Elite suppressors have low frequencies of intact HIV-1 proviral DNA
web
Jan 2, 2025
Science/business updates
external-link
This Baltimore hospital is opening a startup incubator - Technical.ly
googlenews
Jun 1, 2016
Science/business updates
external-link
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo
web
Jan 2, 2025
Science/business updates
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com